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Purpose of the study
Hyperbilirubinemia is the most common laboratory
abnormality in patients treated with ATV; bilirubin
plasma levels have been correlated with ATV plasma con-
centration [1]. In this study we analysed the relationships
between hyperbilirubinemia, Gilbert's syndrome and ATV
plasma concentration.
Methods
HIV-infected subjects on ATV/ritonavir containing stable
HAART regimen were included. ATV plasma concentra-
tions were measured 24 hours after the last dose by HPLC
with UV detector. Polymorphism at the uridin-glocorono-
syl-transferase 1A1 (UGT1A1) was examined in DNA
extracted from blood mononuclear cells, to identify sub-
jects with Gilbert's syndrome. The correlation between
bilirubin plasma levels, ATV concentration and polymor-
phism of UGT1A1 (defined as the presence than at least
one TA7 allele) were evaluated by multivariate linear
regression (other covariates included: gender, age, CD4
count, months of ATV exposure). Predictors of severe
hyperbilirubinemia (>2.5 μmol/l; grade 3) were evaluated
by multivariate logistic regression (polymorphism at
UGT1A1, Cmin, BMI, age included as covariates).
Summary of results
44 patients, 27.3% females, median age of 42.5 years,
median BMI of 23.88 (IQR 21.8–25.8) were analysed. The
distribution of different polymorphism at UGT1A1 was:
45.4% TA6/TA6, 40.9% TA6/TA7, 13.7% TA7/TA7. The
median ATV exposure was 17 months (IQR 7–32), the
median Cmin ATV plasma concentration was 0.60 ng/ml
(IQR 0.41–0.97) and the median plasma bilirubin level
was 2.48 mg/dL (IQR 1.24–3.95). Twenty-two (50%)
patients experienced severe hyperbilirubinemia; among
those, the proportion of patients with polymorphism was
higher: 72% vs. 36% without severe hyperbilirubinemia
(chi-square p = 0.01). In multivariate linear regression
analysis total bilirubin was directly correlated to polymor-
phisms at UGT1A1 (β 1.52 SE 0.61 p = 0.01), to Cmin
ATV plasma levels (β 1.42, SE 0.47 p = 0.04) and to age (β
0.08, SE 0.03 p = 0.007). Polymorphism at UGT1A1 (AOR
6.6, 95%CI 1.34–32.6, p = 0.02) and BMI (for every addi-
tional unit AOR 0.66, 95%CI 0.45–0.97, p = 0.03) were
the only independent predictors of severe hyperbiliru-
binemia.
Conclusion
Screening for Gilbert's syndrome could be an important
tool in patients with a ATV/ritonavir-containing HAART
regimen, in order to predict severe hyperbilirubinemia.
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